Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B. Johnson, Justin M. Balko, Daniel Wang et al.|JCI Insight|2018Cited by 162
MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.Justin M. Balko, Randall S. Davis, Douglas B. Johnson et al.|Journal of Clinical Oncology|2018Cited by 9